Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema 1‑year results from the Japan subgroup of the phase 3 YOSEMITE trial /
Elmentve itt :
| Szerzők: | |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
2023
|
| Sorozat: | JAPANESE JOURNAL OF OPHTHALMOLOGY
67 No. 3 |
| Tárgyszavak: | |
| doi: | 10.1007/s10384-023-00979-8 |
| mtmt: | 33916438 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/27308 |